Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics (NASDAQ: CTNM) reported fourth-quarter 2025 results and affirmed clinical milestones. Key updates: patient dosing started in PROPEL-IPF, a global Phase 2 trial of PIPE-791; topline Phase 1b PIPE-791 data expected Q2 2026; cash, cash equivalents and marketable securities of $262.9M as of Dec 31, 2025, and a projected cash runway into mid-2029. The company completed an upsized public offering, generating $93.0M net proceeds. R&D was $12.8M and net loss was $15.2M in Q4 2025.

#CTNM Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

www.stocktitan.net/news/CTNM/contineum-ther...

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering Contineum Therapeutics (Nasdaq: CTNM) priced an upsized public offering of 7,346,938 Class A shares at $12.25 per share, with gross proceeds expected to be about $90.0 million before fees.The underwriters have a 30‑day option to buy up to an additional 1,102,040 shares. The offering is expected to close on December 15, 2025, subject to customary closing conditions.

#CTNM Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

www.stocktitan.net/news/CTNM/contineum-ther...

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering Contineum Therapeutics (Nasdaq: CTNM) announced a proposed underwritten public offering of $75.0 million of Class A common stock, with a 30-day underwriter option to purchase up to an additional $11.25 million of shares, for potential gross proceeds of up to $86.25 million.The offering is subject to market and other conditions and may not be completed. A related registration statement was filed May 14, 2025 and declared effective by the SEC on May 23, 2025. Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets and William Blair are joint book-running managers.

#CTNM Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

www.stocktitan.net/news/CTNM/contineum-ther...

#CTNM Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

www.stocktitan.net/news/CTNM/contineum-ther...

Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics (NASDAQ: CTNM) reported third-quarter 2025 results and affirmed near-term clinical milestones. The company reported $182.4 million in cash, cash equivalents and marketable securities as of September 30, 2025, and says this cash runway now funds planned operations through 2028. Key clinical catalysts include anticipated topline data from the PIPE-307 Phase 2 VISTA RRMS trial in Q4 2025, initiation of a global PIPE-791 Phase 2 IPF trial in Q4 2025, and expected topline results from a PIPE-791 chronic pain Phase 1b trial in H1 2026. The company generated $19.0 million net proceeds from ATM equity sales in Q3 2025. Q3 operating expense trends: R&D was $11.0 million (+13% YoY) and G&A was $3.9 million (+21% YoY); net loss was $12.8 million.

#CTNM Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

www.stocktitan.net/news/CTNM/contineum-ther...

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones Contineum Therapeutics (NASDAQ: CTNM) has reported its Q2 2025 financial results and clinical development updates. The company ended Q2 with $175.5 million in cash and projects runway through 2027, supplemented by $8.4 million raised through ATM offering in July 2025.Key milestones include anticipated topline data from PIPE-307 Phase 2 VISTA trial for multiple sclerosis in Q4 2025, and initiation of a global Phase 2 trial for PIPE-791 in idiopathic pulmonary fibrosis. The company reported a net loss of $16.0 million in Q2, with R&D expenses increasing 78% to $14.1 million year-over-year.To optimize resources, Contineum has postponed its planned PIPE-791 Phase 2 trial in progressive multiple sclerosis and CTX-343 first-in-human studies to focus on the IPF program.

#CTNM Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

www.stocktitan.net/news/CTNM/contineum-ther...

Contineum's Multiple Sclerosis Drug Trial Expands: Q3 2025 Data Readout Confirmed Latest Phase 1b PET trial progress shows completed enrollment for MS patients and healthy volunteers. Additional patient data to strengthen clinical insights. See Q3 timeline.

#CTNM Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

www.stocktitan.net/news/CTNM/contineum-ther...

JUST IN: ( NASDAQ: #CTNM ) (CTNM) Investment Analysis and Advice

Contineum Therapeutics Nears Major Clinical Milestones: 2 Key Trial Results Coming in 2025, Reports Strong Cash Position Discover upcoming PIPE-791 and PIPE-307 trial results, J&J partnership progress, and robust $190M cash position extending through 2027. Get full pipeline insights.

#CTNM Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

www.stocktitan.net/news/CTNM/contineum-ther...

Charts of the Day - small-cap stocks forming rising three methods candlestick signal, Mon Mar 24th - #CLRB #CTNM - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Can Contineum's $204M War Chest Deliver 6 Clinical Trial Wins? Key Dates Revealed Biotech reports solid $204.8M cash position funding operations through 2027. Multiple Phase 1b/2 trial readouts expected across 2025-2026 in MS, pain, and IPF programs.

#CTNM Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

www.stocktitan.net/news/CTNM/contineum-ther...

Can Contineum's New Non-Opioid Drug Revolutionize Chronic Pain Treatment? PIPE-791 targets osteoarthritis and low back pain through innovative LPA1R mechanism, offering potential alternative to opioids with data expected in 2026.

#CTNM Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791

www.stocktitan.net/news/CTNM/contineum-ther...

Contineum Completes Enrollment Early for Groundbreaking Multiple Sclerosis Treatment Trial Contineum Therapeutics achieves milestone in Phase 2 RRMS trial of PIPE-307, a potential first-in-class therapy, enrolling 168 patients ahead of schedule. Results due Q3 2025.

#CTNM Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

www.stocktitan.net/news/CTNM/contineum-ther...

Contineum Therapeutics Launches Key Phase 1b Trial for Novel Brain-Penetrant MS & IPF Treatment Contineum initiates groundbreaking PET trial for PIPE-791, targeting both progressive MS and IPF through innovative LPA1 receptor antagonism. Data expected Q2 2025.

#CTNM Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

www.stocktitan.net/news/CTNM/contineum-ther...

Just In: ( NASDAQ: #CTNM ) Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

#StockMarket #News

#CTNM Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

www.stocktitan.net/news/CTNM/contineum-ther...

#CTNM Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

www.stocktitan.net/news/CTNM/contineum-ther...

#CTNM Contineum Therapeutics to Attend Upcoming Investor Conferences

www.stocktitan.net/news/CTNM/contineum-ther...